Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi

Edwards Kasonkanji, MPH1; Stephen Kimani, MD1,2; Brent Skiver, MD3; Grace Ellis, BSc4; Ryan Seguin, MPH1; Bongani Kaimila, MD1; Tamiwe Tomoka, MD1,5; Maurice Mulenga, MD6; Nathan Montgomery, MD4; Yuri Fedoriw, MD4; Satish Gopal, MD7; Katherine D. Westmorland, MD1,4; and Matthew S. Painschab, MD1,4

PURPOSE
There are limited data on treatment and outcomes for acute lymphoblastic leukemia (ALL) among adolescents and young adults in sub-Saharan Africa. We describe a prospective observational cohort in Malawi.

METHODS
Patients age 15-39 years with newly diagnosed ALL at Kamuzu Central Hospital, Malawi, were enrolled from 2013 to 2019; follow-up was censored on December 2020. ALL diagnosis was confirmed on-site using immunohistochemistry and telepathology consultation involving pathologists in Malawi and the United States. All but four patients were treated with a modified pediatric-inspired regimen (Cancer and Leukemia Group B 10403 protocol). Key modifications included omission of asparaginase and no dose escalation for methotrexate.

RESULTS
Of 19 participants, the median age was 22 (range 15-36) years. Of the 15 patients who initiated treatment, 11 (73%) achieved remission after induction, one (7%) died during induction, two (13%) had refractory disease, and one (7%) absconded. No patients were lost to follow-up. Eventually, 10 of 11 patients (91%) with confirmed remission relapsed. The median duration of first remission was 10 (range 3-22) months. Twelve of 15 treated patients (80%) had died at the time of censoring. Among treated patients, the 12- and 24-month overall survival was 50% (95% CI, 23 to 72) and 17% (95% CI, 3 to 42), respectively. CNS involvement was associated with worse survival.

CONCLUSION
It is possible to treat adolescents and young adults with ALL in low-resource settings using a low-cost, pediatric-inspired regimen; however, outcomes are poor. Both cost and limitations in supportive care infrastructure limit intensive cytotoxic approaches such as asparaginase. Patient-reported outcomes are needed to understand the quality of life and cost-effectiveness. Critically, innovative, leap-frog therapies, such as monoclonal or bispecific antibodies, and feasible economic models for resource-limited settings are urgently needed.

INTRODUCTION
Acute lymphoblastic leukemia (ALL) is associated with a bimodal age distribution, with one peak in early childhood (median age 8-9 years) and one between the fourth and fifth decades of life. Prognosis is influenced by age and genetic characteristics. Although childhood ALL in high-income countries has very high cure rates of around 90%, outcomes among adults remain poor, with <45% of affected patients expected to achieve long-term disease-free survival. Advancements in intensive therapeutic regimens and the preponderance of favorable genetic characteristics in the pediatric population partly drive the difference in survival outcomes between childhood and adult ALL. Given poor outcomes of ALL among adults, multiple strategies to improve outcomes have been explored.

One key observation is that adolescents and young adults (AYAs; defined as age 15-39 years) with ALL treated on pediatric-inspired regimens have better outcomes, including survival, hospital time, toxicities, late effects, and quality of life during and after treatment compared with adult oncology regimens. In the recently published Cancer and Leukemia Group B (CALGB) 10403 study, after 3 years, 73% of participants had achieved and remained in remission. Unfortunately, descriptions of treatment and outcomes of nonpediatric ALL from low- and middle-income countries, where treatment is challenging because of limited supportive care infrastructure, are scarce. Additional challenges include lack of access to frontline drugs such as asparaginase, poor diagnostic infrastructure, high treatment default rates, and toxicity-related complications. This study provides
one of the first descriptions of treatment and outcomes of
ALL among AYAs treated with a pediatric-inspired regimen in a low-resource setting.

METHODS
We identified newly diagnosed, pathologically confirmed ALL in patients age 15-39 years enrolled in an observational, prospective cohort at Kamuzu Central Hospital from June 2013 to December 2019. Kamuzu Central Hospital is a referral hospital located in Lilongwe, the capital city of Malawi, that provides cancer diagnostic and treatment services to a catchment area of approximately nine million people.

All patients underwent a comprehensive baseline evaluation, including chest x-ray, abdominal ultrasound, CSF cytology, diagnostic bone marrow evaluation, and excisional lymph node biopsy (if applicable). In addition, immunophenotyping was performed on-site in Malawi using immunohistochemical stains for CD3 (clone PS1), CD20 (clone L26), CD30 (clone 15B3), CD45 (code NCL-L-LCA-RP), CD138 (clone MI15), BCL2 (clone bcl-2/100/D5), Ki-67 (clone MM1), and TdT (clone TdT-338) from Leica Biosystems (Buffalo Grove, IL). Pathology assessments were supported by real-time telepathology consultations involving two to four pathologists in Malawi and the United States. The US-based pathologists participated in weekly consensus telepathology conferences with the Malawi-based colleagues and confirmed cases subsequently underwent a secondary review of cases in Chapel Hill as previously described.

Patients were treated with a modified regimen modeled after the CALGB10403 protocol for AYAs. Treatment phases included induction, consolidation, interim maintenance, delayed intensification, and maintenance (Table 1). However, because of resource limitations within the public health system, we omitted asparaginase from the regimen, and we did not initially escalate methotrexate during interim maintenance because of the inability to measure methotrexate levels and possible differences in methotrexate clearance in different populations. The latter has subsequently been implemented without complications. Postinduction bone marrow biopsy was used to assess remission status. All patients received standardized antiinfective prophylaxis with ciprofloxacin, fluconazole, and cotrimoxazole during induction until neutrophil count recovery (ie, absolute neutrophil count ≥ 500 × 10^9 cells/L), with the continuation of cotrimoxazole and acyclovir throughout the treatment courses.

We actively followed patients until death or administrative censoring on December 31, 2020. Possible outcomes included alive, dead, lost to follow-up (defined as no form of contact after > 3 phone calls and physical tracing), and absconded (defined as abandoning treatment but still able to contact the participant).

We used descriptive statistics to assess patient characteristics and overall survival (OS) using Kaplan-Meier methods. Univariate analysis of predictors of OS were compared by the log-rank test. We used Stata version 13 (College Station, TX) and R (Vienna, Austria) to analyze data; figures were produced using the R package ggplot2. This study was approved by the Malawi National Health Science Research Committee and the Institutional Review Board of the University of North Carolina at Chapel Hill. All patients provided written informed consent.

RESULTS
Baseline Characteristics
From June 2013 to December 2019, we identified 19 AYAs with newly diagnosed ALL (Table 2). Thirteen patients (68%) were male, and the median age was 19 (range 15-36) years. All patients were HIV-negative. At diagnosis, 10 patients (53%) endorsed symptoms for 3 months or
### TABLE 1. C10403 Regimen Versus Modified C10403 Regimen

| Treatment Phase | Original CALGB 10403 Regimen | Modified CALGB 10403 Regimen for Malawi |
|-----------------|-------------------------------|----------------------------------------|
| **Induction** (course I) | Allopurinol 300 mg daily | Vincristine 1.5 mg/m² (2 mg max) IV (once weekly on days 1, 8, 15, and 22) |
|                  | Vincristine 1.5 mg/m² (2 mg max) IV (once weekly on days 1, 8, 15, and 22) | Doxorubicin 25 mg/m² IV (once weekly on days 1, 8, 15, and 22) |
|                  | Daunorubicin 25 mg/m² IV (once weekly on days 1, 8, 15, and 22) | Prednisone 60 mg/m²/d PO/IV in two divided doses (days 1-28) |
|                  | PEG-asparaginase 2,500 IU/m² IM or IV (on day 4) | IT-methotrexate 15 mg IT (once on days 8 and 29) |
|                  | IT-cytarabine 70 mg IT (on course 1) | IT-methotrexate 15 mg IT (once on days 8 and 29) |
|                  | IT-methotrexate 15 mg IT (on course 1) | IT-methotrexate 15 mg IT (once on days 8 and 29) |
| **Extended induction** (if required; course IA) | Prednisone 60 mg/m²/d PO/IV in two divided doses (days 1-14) | Prednisone 60 mg/m²/d PO/IV in two divided doses (days 1-14) |
|                  | Daunorubicin 25 mg/m² IV (once on day 1) | Doxorubicin 25 mg/m² IV (once on day 1) |
|                  | Vincristine 1.5 mg/m² (2 mg max) IV (once on days 1 and 8) | Vincristine 1.5 mg/m² (2 mg max) IV (once on days 1 and 8) |
|                  | PEG-asparaginase 2,500 IU/m² IM or IV (on day 4) | PEG-asparaginase 2,500 IU/m² IM or IV (on day 4) |
| **Consolidation** (course II) | Cyclophosphamide 1,000 mg/m² IV (once on days 1 and 29) | Cyclophosphamide 1,000 mg/m² IV (once on days 1 and 29) |
|                  | Cytarabine 75 mg/m² IV or SC (once per day on days 1-4, 8-11, 29-32, and 36-39) | Cytarabine 75 mg/m² IV or SC (once per day on days 1-4, 8-11, 29-32, and 36-39) |
|                  | 6-Mercaptopurine 60 mg/m² PO (once per day on days 1-14 and 29-42) | 6-Mercaptopurine 60 mg/m² PO (once per day on days 1-14 and 29-42) |
|                  | Vincristine 1.5 mg/m² (2 mg max) IV (once on days 15, 22, 43, and 50) | Vincristine 1.5 mg/m² (2 mg max) IV (once on days 15, 22, 43, and 50) |
|                  | PEG-asparaginase 2,500 IU/m² IM or IV (on day 15 and 43) | IT-methotrexate 15 mg IT (once on days 1, 8, 15, and 22) |
|                  | IT-methotrexate 15 mg IT (once on days 1, 8, 15, and 22) | IT-methotrexate 15 mg IT (once on days 1, 8, 15, and 22) |
| **Interim maintenance** (course III) | Vincristine 1.5 mg/m² (2 mg max) IV (once on days 1, 11, 21, 31, and 41) | Vincristine 1.5 mg/m² (2 mg max) IV (once on days 1, 11, 21, 31, and 41) |
|                  | Methotrexate 100 mg/m² IV (escalate by 50 mg/m²/dose as tolerated; once on days 1, 11, 21, 31, and 41) | Methotrexate 100 mg/m² IV (fixed dose) (once on days 1, 11, 21, 31, and 41) |
|                  | PEG-asparaginase 2,500 IU/m² IM or IV (on days 2 and 22) | IT-methotrexate 15 mg IT (once on days 1 and 31) |
|                  | IT-methotrexate 15 mg IT (once on day 1 and 31) | IT-methotrexate 15 mg IT (once on days 1 and 31) |
| **Delayed intensification** (course IV) | Vincristine 1.5 mg/m² (2 mg max) IV (once on days 1, 8, 15, 43, and 50) | Vincristine 1.5 mg/m² (2 mg max) IV (once on days 1, 8, 15, 43, and 50) |
|                  | Dexamethasone 10 mg/m² PO or IV twice a day (days 1-7 and 15-21) | Dexamethasone 10 mg/m² PO or IV twice a day (days 1-7 and 15-21) |
|                  | Daunorubicin 25 mg/m² IV (once on days 1, 8, and 15) | Daunorubicin 25 mg/m² IV (once on days 1, 8, and 15) |
|                  | PEG-asparaginase 2,500 IU/m² IM or IV (on days 4 or 5 or 6 and 43) | Cyclophosphamide 1,000 mg/m² IV (once on day 29) |
|                  | Cyclophosphamide 1,000 mg/m² IV (once on day 29) | Cytarabine 75 mg/m² IV or SC (once per day on days 29-32 and 36-39) |
|                  | 6-Thioguanine 60 mg/m²/d PO (once per day on days 29-42) | IT-methotrexate 15 mg IT (once on days 29-32 and 36-39) |
|                  | IT-methotrexate 15 mg IT (once on days 29, 36, and 37) | IT-methotrexate 15 mg IT (once on days 29, 36, and 37) |
| **Maintenance** (course V) | Vincristine 1.5 mg/m² (2 mg max) IV (once on days 1, 29, and 57) | Vincristine 1.5 mg/m² (2 mg max) IV (once on days 1, 29, and 57) |
|                  | Dexamethasone 6 mg/m²/d PO or IV twice a day (days 1-5, 29-33, and 57-61) | Dexamethasone 6 mg/m²/d PO or IV twice a day (days 1-5, 29-33, and 57-61) |
|                  | 6-Mercaptopurine 75 mg/m² PO (once per day on days 1-84) | 6-Mercaptopurine 75 mg/m² PO (once per day on days 1-84) |
|                  | Methotrexate 20 mg/m² PO (once weekly on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78) | Methotrexate 20 mg/m² PO (once weekly on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78) |
|                  | IT-methotrexate 15 mg IT (once on days 1 and 29) | IT-methotrexate 15 mg IT (once on days 1 and 29) |

NOTE. Antimicrobial prophylaxis: ciprofloxacin 500 mg twice a day and fluconazole 400 mg once daily when the absolute neutrophil count < 0.5 × 10⁹ cells/L; bactrim prophylaxis is given throughout but held during IV methotrexate; acyclovir prophylaxis is given throughout. Differences are italicized.

Abbreviations: CALGB, Cancer and Leukemia Group B; IM, intramuscular; IT, intrathecal; IV, intravenous; max, maximum; PEG, polyethylene glycol; PO, orally, SC, subcutaneous.

*Mercaptopurine given as 50 mg tabs. Dosing depends on individual patient exactly how it is given. Spread out the tablets as evenly as possible over the week to get as close as possible to 420 mg/m²/week during consolidation and 525 mg/m²/week during maintenance.

*Before 2018, only two doses of IT chemotherapy were given during the consolidation phase, rather than the planned four.

*Dose escalation implemented in 2018.

*Maintenance therapy consisted of 12-week courses continuing until 3 years from initiation of interim maintenance for male and 2 years for female patients.

*Healed on day 29 of the first four courses when IT methotrexate is given.

fewer; three had a history of tuberculosis treatment, including two for whom tuberculosis treatment was prescribed for adenopathy related to their leukemia. Twelve (63%) had an Eastern Cooperative Oncology Group performance status of ≥ 2. Six (32%) patients had CNS involvement at the time of presentation. Eleven (58%)
patients had T-cell ALL by immunohistochemistry. Six (32%) patients presented with leukocytosis ≥ 50 × 10^9/L, including three with hyperleukocytosis (WBC > 100 × 10^9/L).

Treatment Characteristics and Toxicity

Fifteen patients started therapy, and because of relapse or death, 11 (73%) entered consolidation, eight entered interim maintenance, seven entered delayed intensification, and five entered maintenance (Table 3). Toxicity varied by treatment course; during the course of therapy, nine (60%) participants experienced grade 3 or 4 neutropenia, and most commonly during induction, five (33%) experienced grade 3 or 4 anemia and six (40%) experienced grade 3 or 4 thrombocytopenia. Nonhematologic grade 3 or 4 toxicities that occurred on greater than one occasion included vomiting, diarrhea, epistaxis, constipation, and decreased vision.

Outcomes

As of December 31, 2020, no patients were lost to follow-up. The median time from screening to chemotherapy initiation was 7 (range 0-44) days, during which patients could receive prephase corticosteroids. Four patients died before initiating chemotherapy (Fig 1). Of 15 patients who initiated treatment, 11 (73%) achieved remission after induction, one (7%) died during induction, two (13%) had refractory disease, and one (7%) absconded without achieving remission. Subsequently, 10 of 11 (91%) who initially achieved remission relapsed, including one patient who absconded shortly after achieving remission. The median duration of remission was 10 (range 3-22) months. All remissions were bone marrow remissions with peripheral blasts and cytopenias; there were no documented cases of CNS relapse. As of December 31, 2020, three patients were alive: one remained in remission, off maintenance chemotherapy, and without evidence of progression at 56 months, one was in remission in the maintenance phase, and one was censored after being refractory to induction and transferring care to the pediatric center. Of the 15 patients who began chemotherapy, 12 (80%) died, and only one (7%) death was possibly treatment-related.

Event-free survival, defined as relapse, and loss to follow-up, treatment abandonment, or death at 12 and 24 months were 26% (95% CI, 12 to 56) and 5% (95% CI, 1 to 36), respectively. Among treated patients, the

### Table 2. Baseline Characteristics of Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia Treated in Lilongwe, Malawi (2013-2019)

| Characteristic | N = 19 |
|---------------|-------|
| Age, years, median [IQR] | 19 [15-36] |
| Male sex, No. (%) | 13 (68) |
| HIV-negative, No. (%) | 19 (100) |
| Self-reported symptom duration ≤ 3 months, No. (%) | 10 (53) |
| Any history of tuberculosis treatment, No. (%) | 3 (16) |
| ECOG PS ≥ 2, No. (%) | 12 (63) |
| CNS involvement, No. (%) | 6 (32) |
| Not evaluated/unknown | 4 (21) |
| Immunophenotype, No. (%) | | |
| B-cell | 8 (42) |
| T-cell | 11 (58) |
| Hemoglobin, median [IQR] | 6.1 [3.7-14.7] |
| Absolute neutrophil count, median [IQR],a 10^9/L | 1.6 [0.2-8.5] |
| Lymphocyte count, median [IQR],a 10^9/L | 4.0 [0.8-78.6] |
| Platelets, median [IQR], 10^9/L | 55.0 [1.0-411] |
| WBC, median [IQR], 10^9/L | 9.5 [1.2-166.5] |
| WBC ≥ 50,000, No. (%), 10^9/L | 6 (32) |
| LDH, median [IQR]b,c | 690 [242-4,929] |

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; IQR, interquartile range; LDH, lactate dehydrogenase.

aMissing 1.

bLaboratory upper limit of normal 250 IU/L.

cMissing 3.

### Table 3. Number of Patients Initiating and Completing Each Course of Treatment and Grade 3 or 4 Treatment Toxicity for Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia Treated With a Modified Cancer and Leukemia Group B 10403 Protocol in Lilongwe, Malawi (2013-2019)

| Phase of Therapy | Participants Who Initiated Phase (No.) | Participants Who Completed Phase (No.) | Anemia (No.) | Neutropenia (No.) | Thrombocytopenia (No.) | Nonhematologic Toxicity (No.) |
|------------------|----------------------------------------|----------------------------------------|--------------|------------------|------------------------|-------------------------------|
| Remission induction (course I) | 15 | 11 | 1 | 9 | 1 | Constipation (n = 2), vision decreased (n = 1), epistaxis (n = 1), diarrhea (n = 1), urinary tract infection (n = 1), vomiting (n = 1) |
| Remission consolidation (course II) | 11 | 8 | 2 | 3 | 3 | Diarrhea (n = 2), noncardiac chest pain (n = 1), lung infection (n = 1), epistaxis (n = 1), vomiting (n = 1) |
| Interim maintenance (course III) | 8 | 7 | 1 | 0 | 0 | None |
| Delayed intensification (course IV) | 7 | 5 | 0 | 1 | 1 | Vision decreased (n = 1), nausea (n = 1), vomiting (n = 1) |
| Maintenance (course V) | 5 | 1 | 1 | 3 | 1 | Diarrhea (n = 1), rectal hemorrhage (n = 1) |
FIG 1. Treatment outcomes for adolescents and young adults with acute lymphoblastic leukemia treated in Lilongwe, Malawi (2013-2019), shown as a swimmer plot.

Survival and cure rates with the regimen used in this study were lower than desired. The use of a modified pediatric regimen to treat ALL among AYAs in Malawi resulted in the 12- and 24-month OS of 50% and 17%. Although this is expectedly poor compared with outcomes for AYAs in high-resource settings (3-year progression free survival of 59% in CALGB10403), it is similar to published outcomes among pediatric ALL from the region.12,15,16 For reference, the 2-year OS rate for a predominantly pediatric population receiving an asparaginase-based pediatric regimen for ALL in Rwanda was 22%.12 Unsurprisingly, in our study, poor outcomes were related to ALL progression and NOT toxicity, similar to published data for ALL among children in Malawi and Rwanda.12,16

Studies from high-income settings suggest that including asparaginase in pediatric-inspired protocols for AYAs with ALL is critically important. In large cohorts of pediatric and AYA ALL patients from high-income countries, discontinuation of asparaginase at any point during therapy was associated with a 5%-10% increase in absolute risk of relapse.17,18 The increased risk of relapse may be due to other factors correlated with discontinuation of asparaginase, but certainly the ability to implement complete, maximum-intensity courses of ALL therapy is critically important for survival of patients with ALL. Because of cost and difficulties with implementation, such as management of hypersensitivity and adverse events, asparaginase is not available in the Malawi public health sector and was therefore not included in the regimen reported in this article.6,19 Furthermore, compared with children, asparaginase is more challenging to administer in adults because of increased adverse events.19,20 Therefore, the effect on survival in sub-Saharan Africa should be explored systematically and, perhaps, adult regimens without asparaginase21 or leap-frog regimens including monoclonal antibody therapies22,23 or bispecific antibodies24 will be more effective in resource-limited settings if equitable price models can be arranged.

CNS involvement at baseline was quite common and predicted poor outcomes in this study. The incidence of CNS disease at presentation in our study is much higher than that seen in high-income countries where it is typically < 10%.25 This may be due to chance (ie, small sample size), late presentation of disease, or differences in biology although additional studies are needed to further explore this. In addition, CNS involvement at baseline was associated with increased mortality in our study. This is in line with data from high-income countries where CNS involvement is a poor prognostic factor in adult ALL. Multiple factors might have contributed to this outcome in our population; some have been acted on, and others are room for improvement. Critically, any of the treatments that are typically given for CNS disease are not available in the case of cranial irradiation, not routinely given because of risk of high toxicity with the inability to monitor levels in the case of high-dose intravenous methotrexate, or difficult to implement consistently in the

event-free survival at 12 and 24 months was 33% (95% CI, 16 to 68) and 7% (95% CI, 1 to 44), respectively. The OS at 12 and 24 months (N = 19) was 40% (95% CI, 18 to 61) and 14% (95% CI, 2 to 34), respectively. Among treated patients (n = 15), the 12- and 24-month OS was 50% (95% CI, 23 to 72) and 17% (95% CI, 3 to 42), respectively (Fig 2A). In univariate Kaplan-Meier analysis comparing baseline characteristics, only baseline CNS involvement was associated with worse survival (P = .02; Fig 2B).

DISCUSSION

To our knowledge, this is the first description of treatment and outcomes of ALL among AYAs in sub-Saharan Africa. We enrolled participants with advanced disease characteristics (63% Eastern Cooperative Oncology Group ≥ 2, 84% extramedullary involvement, and 32% white cell count > 50 × 10⁹ cells/L). Our study provides one of the most well-characterized cohorts of ALL among AYAs in the region. No patients were lost to follow-up. We initiated treatment at a median of 7 days after the initial screening visit, and we were able to maintain patients in treatment with minimal treatment abandonment, a common confounding factor in the pediatric hematologic malignancy literature from the region.12-14
case of weekly or twice weekly intrathecal chemotherapy until blast clearance. Each of these are potential areas to target for improvement of outcomes in this population.

Furthermore, in addition to asparaginase availability and treatment of CNS disease, a number of other factors might have contributed to the poor survival outcomes in this study, including, among others, lack of oncology specialists, social determinants of health including poverty and distance from care in a largely rural population, and physical and human resources that may affect prevention and management of toxicities. In addition, survival for some patients in this age group could have been improved with access to Philadelphia chromosome testing tyrosine kinase inhibitor therapy; however, testing and therapy for Philadelphia chromosome have only recently become available. Context-appropriate implementation studies measuring, evaluating, and/or addressing possible contributing factors are urgently needed to assess the effects on outcomes and toxicity.

Our study included a small sample of patients treated at a single tertiary care center in Malawi, and its findings may not be generalized. However, given the lack of similar data from sub-Saharan Africa, our results could inform emerging cancer treatment programs and priorities in the region. Our experience reflects several noteworthy achievements for a difficult-to-treat population in a low-resource setting. First, we robustly identified and characterized ALL, including immunophenotyping. Second, we implemented a contemporary protocol under local conditions adapted from current high-income country practice, which led to the induction of histologically confirmed remission in most patients. Third, we had a minimal loss to follow-up despite a long treatment course. Finally, despite eventual disease progression and manageable toxicity, treatment was delivered on a largely outpatient basis, and patients were able to spend time with their families. Although not formally assessed in this study, we plan to incorporate the use of patient-reported instruments to capture quality of life and symptom burden in this population.

In conclusion, our experience demonstrates that it is possible to deliver a complex chemotherapy regimen in a highly resource-constrained setting although limitations in treatment intensity because of supportive care limitations and asparaginase availability contributed to poor OS for what is a highly curable disease in high-income countries. Context-specific refinement of ALL treatment in resource-limited settings to better approximate curative standards of care in high-income countries will likely lead to improved outcomes. Stakeholders have an ethical imperative to achieve equitable access to curative therapies regardless of the setting.

**AFFILIATIONS**

1. University of North Carolina Project-Malawi, Lilongwe, Malawi
2. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
3. Messino Cancer Center, Asheville, NC
4. Lineberger Comprehensive Cancer, University of North Carolina, Chapel Hill, NC
5. University of Malawi College of Medicine, Blantyre, Malawi
6. Malawi Ministry of Health, Lilongwe, Malawi
7. Center for Global Health, National Cancer Institute, Rockville, MD

**CORRESPONDING AUTHOR**

Matthew S. Painschab, MD, UNC Project Malawi, Tidziwe Building, Private Bag A-104, Lilongwe, Malawi; e-mail: painschabm@med.unc.edu.

FIG 2. OS for adolescent and young adult patients with ALL (A) among all patients who initiated treatment (n = 15) in Lilongwe, Malawi (2013-2019) and (B) by CNS involvement at baseline. No: not involved; yes: involved; unknown: no clinical signs of CNS involvement but CNS not evaluated before treatment initiation. ALL, acute lymphoblastic leukemia; OS, overall survival.
This work was completed while S.G. was employed at the University of North Carolina at Chapel Hill. The opinions expressed in this article are the authors own and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, or the United States Government. The funding agencies had no role in study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit it for publication.

E.K. and S.K. contributed equally to this work.

Presented in abstract form at the 9th annual American Society of Clinical Oncology/National Cancer Institute Center for Global Health 9th annual Symposium on Global Cancer Research (March), 10-11, 2021.

Supported by the National Institutes of Health (U54CA190152, U54CA254564, K01TW011191, D43TW009340, UM1CA121947, and K01TW0111470).

Conception and design: Stephen Kimani, Yuri Fedoriw, Satish Gopal, Matthew S. Painschab

Financial support: Satish Gopal

Administrative support: Satish Gopal

Provision of study materials or patients: Maurice Mulenga, Satish Gopal

Collection and assembly of data: Edwards Kasonkanji, Stephen Kimani, Brent Skiver, Grace Ellis, Ryan Seguin, Bongani Kaimila, Tamie Westmorland, Matthew S. Painschab

Data analysis and interpretation: Edwards Kasonkanji, Stephen Kimani, Grace Ellis, Tamie Tomoka, Yuri Fedoriw, Satish Gopal, Katherine D. Westmorland, Matthew S. Painschab

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rcw or ascopubs.org.go/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Brent Skiver

Employment: American Oncology Network

Honoraria: Curio Science

Travel, Accommodations, Expenses: American Oncology Network

Nathan Montgomery

Employment: Tempus

Consulting or Advisory Role: Premier Inc

Yuri Fedoriw

Honoraria: Alexion Pharmaceuticals

No other potential conflicts of interest were reported.

We thank patients and their families for participation in our study and recognize the leadership of Kamuzu Central Hospital, UNC Project-Malawi, and Lineberger Comprehensive Cancer Center for their support of this study.
16. Chagaluka G, Carey P, Banda K, et al: Treating childhood acute lymphoblastic leukemia in Malawi. Haematologica 98:e1-e3, 2013
17. Gupta S, Wang C, Raetz EA, et al: Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: A report from the Children’s Oncology Group. J Clin Oncol 38:1897-1905, 2020
18. Gottschalk Højfeldt S, Grell K, Abrahamsson J, et al: Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia. Blood 137:2373-2382, 2021
19. Boissel N, Sender LS: Best practices in adolescent and young adult patients with acute lymphoblastic leukemia: A focus on asparaginase. J Adolesc Young Adult Oncol 4:118-128, 2015
20. Egler R, Ahuja S, Matloub Y: L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother 7:62-71, 2016
21. Kantarjian H, Thomas D, O’Brien S, et al: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101:2788-2801, 2004
22. Maury S, Chevret S, Thomas X, et al: Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med 375:1044-1053, 2016
23. Kantarjian HM, DeAngelo DJ, Stelljes M, et al: Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375:740-753, 2016
24. Kantarjian H, Stein A, Gokbuget N, et al: Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376:836-847, 2017
25. Larson RA: Managing CNS disease in adults with acute lymphoblastic leukemia. Leuk Lymphoma 59:3-13, 2018